ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung
Both
Carcinoma, Non-Small-Cell Lung
Trial Information
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
Inclusion Criteria:
- You have a diagnosis of non-small cell lung cancer.
- You have received no prior chemotherapy.
- You have at least one measurable lesion.
- You have an adequate performance status.
- You are at least 18 years of age.
Exclusion Criteria:
- You have previously received chemotherapy for your lung cancer.
- You have received radiation within the last 30 days.
- You have active infection or other serious condition.
- You have brain metastasis.
- You have recently lost a significant amount of weight.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
6142
NCT ID:
NCT00051493
Start Date:
April 2002
Completion Date:
December 2002
Related Keywords:
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Lung Cancer
- NSCLC
- Advanced Non-Small Cell Lung Cancer
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Austin, Texas 78705 |
